ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0949

The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis

Mehrnaz Gharaee-Kermani1, Poulami Dey2, Vincent van Drongelen1, Joanna Rew1, Rachael Bogle3, Marisa Hildebrandt1, Benjamin Klein1, Rezvan Moallemian1, Monique E Verhaegen1, Andrzej A Dlugosz4, Lam Tsoi1, J. Michelle Kahlenberg1, Johann Gudjonsson1 and Allison C Billi1, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, Ann Arbor, MI, 3University of Michigan, Holland, OH, 4University of Michigan, Ann Arbor

Meeting: ACR Convergence 2025

Keywords: Animal Model, autoimmune diseases, Fibroblasts, Dermal, lupus-like disease, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoimmune disease is far more common in women than men. We have determined that the skin of healthy women is primed for autoimmunity due to increased baseline epidermal expression of the transcription coregulator VGLL3. Accordingly, VGLL3 overexpression in transgenic (TG) mouse epidermis causes cutaneous and systemic murine lupus. Intriguingly, VGLL3 is also reported to act variably as an oncogene and tumor suppressor, revealing pleiotropic roles. While fibrosis is a hallmark of multiple autoimmune skin diseases, few animal models successfully recapitulate fibrosis, limiting mechanistic investigation.

Methods: Trichrome staining, immunostaining, qPCR, bulk RNA-seq, and single-cell RNA-seq (scRNA-seq) were used to analyze skin from mouse models of epidermal VGLL3 overexpression and human skin from patients with cutaneous lupus and healthy controls. Seurat, IPA, CellChat, and CellPhoneDB were used for analysis of scRNA-seq data. Human keratinocytes overexpressing VGLL3 and primary human skin fibroblasts were used for conditioned media experiments.

Results: We demonstrate that epidermal VGLL3 also drives autoimmune skin fibrosis. Integrating single-cell transcriptomic data from TG mice and human lupus patients, we establish a role for VGLL3-overexpressing keratinocytes in initiating autoimmune skin fibrosis through altering fibroblast transcriptional states. In pre-lesional skin, VGLL3-overexpressing keratinocytes upregulate specific cytokines including TNF and CCL20 and promote an interferon-rich environment, inducing pre-lesional fibroblasts to activate a profibrotic, proinflammatory transcriptional program implicated in fibrotic disease. Conditioned media experiments confirm a direct effect of keratinocytes on fibroblasts, increasing transcription of CCL2, a chemokine implicated in multiple fibrotic diseases. Analysis of fibroblasts reveals expansion in pre-lesional and lesional skin of a population of profibrotic fibroblasts that are shown by ligand-receptor analysis to be one of the most differentially activated cellular communicators in diseased skin. Fibroblast subclustering identifies a transgenic mouse-specific cluster of Tnc-positive fibroblasts, which have been shown to be crucial in the progression and maintenance of fibrotic skin diseases by promoting fibroblast activation and sustaining fibrotic responses. Analysis of human cutaneous lupus scRNA-seq data corroborates many of our murine lupus findings in human disease.

Conclusion: These results suggest that VGLL3 and keratinocytes play a dual role in early autoimmune skin fibrosis through both fibroblast reprogramming and immune cell recruitment and support the use of the K5-Vgll3 model for investigation of autoimmune skin fibrosis.

Supporting image 1Figure 1. Epidermal VGLL3 overexpression leads to autoimmune skin fibrosis.

A. Gross images of female and male transgenic (TG) and wild-type (WT) mice with epidermal overexpression of Vgll3.

B. H&E staining of murine lesional TG and WT skin and human lupus patient and healthy control skin.

C. Trichrome staining of murine and human skin as in (B).

D. CTGF/CCN2 immunohistochemistry (IHC) of murine and human skin as in (B).

Supporting image 2Figure 2. Single-cell RNA-sequencing (scRNA-seq) reveals immune cell expansion in skin lesions induced by epidermal VGLL3 overexpression

A. Uniform Manifold Approximation and Projections (UMAPs) of all cells colored by cell type in healthy (H), nonlesional transgenic (N), and lesional transgenic (L) mouse skin.

B. Dot plot of representative marker genes for each cell type.

C. Histogram of all cells colored by cell type across disease states. Red boxes, immune cells.

Supporting image 3Figure 3. Fibroblast subclustering reveals emergence of Tnc-expressing fibroblasts in nonlesional and lesional transgenic mouse skin.

A. Fibroblast subclustering across disease states. Red arrows indicate Tnc fibroblasts (FBs) (cells in orange).

B. Histogram of fibroblast subclusters across disease states. Red boxes indicate Tnc fibroblasts (bars in light blue).

C. Dot plot of representative marker genes for each cell type. Red boxes indicate Tnc fibroblasts.


Disclosures: M. Gharaee-Kermani: None; P. Dey: None; V. van Drongelen: None; J. Rew: None; R. Bogle: None; M. Hildebrandt: None; B. Klein: None; R. Moallemian: None; M. Verhaegen: None; A. Dlugosz: None; L. Tsoi: Galderma, 5, Janssen, 5; J. Kahlenberg: AstraZeneca, 1, Aurinia Pharmaceuticals, 1, Avion Pharmaceuticals, 1, Biogen, 1, Boehringer-Ingelheim, 1, Bristol-Myers Squibb(BMS), 1, 5, Danger Bio, 1, Eli Lilly, 1, Exo Therapeutics, 2, GlaxoSmithKlein(GSK), 2, Janssen, 5, Provention Bio, 1, Q32 Bio, 5, Rome Therapeutics, 2, 5, Ventus, 2, 5; J. Gudjonsson: None; A. Billi: None.

To cite this abstract in AMA style:

Gharaee-Kermani M, Dey P, van Drongelen V, Rew J, Bogle R, Hildebrandt M, Klein B, Moallemian R, Verhaegen M, Dlugosz A, Tsoi L, Kahlenberg J, Gudjonsson J, Billi A. The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-cancer-associated-female-biased-factor-vgll3-drives-autoimmunity-and-fibrosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-cancer-associated-female-biased-factor-vgll3-drives-autoimmunity-and-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology